



NEWS RELEASE

May 15, 2023

Plakous Therapeutics Announces New Board Member James Kalinovich

WINSTON-SALEM, N.C.– Plakous Therapeutics, Inc. is excited to announce the addition of James Kalinovich to its Board of Directors. James brings strong financial expertise with 30 years in corporate finance, M&A, and several successful IPOs. James has been a strong supporter of Plakous for the past several years and has been instrumental in its fund-raising efforts over that time. As the company prepares for its first equity raise, a \$15 million Series A, James will provide critical insight and support to ensure the company is well positioned.

Robert Boyce, Plakous CEO said, “James brings a skill set to the board that complements our existing board members. I look forward to continuing a collaboration with James that has been ongoing for the past several years. We are fortunate to have James join the board at this critical point in our development.”

“I am a strong believer in the company’s product, Protego-PD™, and its commitment to saving the lives of thousands of severely premature babies every year by preventing the devastating effects of Necrotizing Enterocolitis,” said James. He went on to say, “I also feel that the management team is well balanced and positioned to successfully navigate the clinical and regulatory requirements necessary to bring Protego-PD™ to market. I look forward to contributing to the company’s success.

Necrotizing Enterocolitis (NEC) is a devastating disease with a 30% mortality rate. NEC affects premature infants with very low birthweight (those born weighing less than three pounds) and is caused by runaway inflammation in a premature/underdeveloped intestine. Managing NEC consumes nearly \$4.0 billion in healthcare expenditures annually. Plakous seeks to prevent NEC by accelerating intestinal maturation of premature infants with Protego-PD™.

About Plakous Therapeutics, Inc.

Plakous Therapeutics is a biotherapeutic company dedicated to researching and developing placenta derived regenerative therapies to improve patient outcomes and reduce health care costs. For more information, please visit the company’s website at plakoustherapeutics.com.

Contact:

Robert Boyce
CEO, Plakous Therapeutics
908-625-3295